SEC Company Response from ProQR Therapeutics N.V. (PRQR) (CIK 0001612940) (PRQR) — Nov 15, 2018
ProQR Therapeutics N.V. (PRQR) (CIK 0001612940)
Date: Nov. 15, 2018 · CIK: 0001612940 · Accession: 0001104659-18-068781
AI Filing Summary & Sentiment
File numbers found in text: 333-228251
Letter
ProQR Therapeutics N.V.
Zernikedreef 9
2333 CR Leiden
The Netherlands
31 88 166 7000
VIA EDGAR
November 15, 2018
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549-4720
Re: ProQR Therapeutics N.V.
Acceleration Request for Registration Statement on Form F-3
File No. 333-228251
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), ProQR Therapeutics N.V. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to November 19, 2018, at 4:00 p.m., Eastern Time, or as soon thereafter as possible. If you have any questions regarding this request, please contact Danielle M. Lauzon of Goodwin Procter LLP at (617) 570-1955.
Signature Page Follows
Sincerely,
PROQR THERAPEUTICS N.V.
Show Raw Text
CORRESP 1 filename1.htm ProQR Therapeutics N.V. Zernikedreef 9 2333 CR Leiden The Netherlands 31 88 166 7000 VIA EDGAR November 15, 2018 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-4720 Re: ProQR Therapeutics N.V. Acceleration Request for Registration Statement on Form F-3 File No. 333-228251 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), ProQR Therapeutics N.V. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to November 19, 2018, at 4:00 p.m., Eastern Time, or as soon thereafter as possible. If you have any questions regarding this request, please contact Danielle M. Lauzon of Goodwin Procter LLP at (617) 570-1955. Signature Page Follows Sincerely, PROQR THERAPEUTICS N.V. /s/ Daniel de Boer Daniel de Boer Chief Executive Officer cc: Smital Shah, ProQR Therapeutics N.V. Paul van Dongen, ProQR Therapeutics N.V. Mitchell S. Bloom, Goodwin Procter LLP Danielle M. Lauzon, Goodwin Procter LLP